These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1238 related items for PubMed ID: 20839290

  • 1. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR.
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [Abstract] [Full Text] [Related]

  • 2. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC.
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [Abstract] [Full Text] [Related]

  • 3. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [Abstract] [Full Text] [Related]

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J.
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [Abstract] [Full Text] [Related]

  • 5. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.
    Smith MR, Saad F, Egerdie B, Sieber P, Tammela TLj, Leder BZ, Ke C, Goessl C.
    J Bone Miner Res; 2011 Dec; 26(12):2827-33. PubMed ID: 21898590
    [Abstract] [Full Text] [Related]

  • 6. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 7. Traditional and novel bone remodeling markers in premenopausal and postmenopausal women.
    Botella S, Restituto P, Monreal I, Colina I, Calleja A, Varo N.
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1740-8. PubMed ID: 24001743
    [Abstract] [Full Text] [Related]

  • 8. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group.
    N Engl J Med; 2006 Feb 23; 354(8):821-31. PubMed ID: 16495394
    [Abstract] [Full Text] [Related]

  • 9. Reference intervals for serum concentrations of three bone turnover markers for men and women.
    Michelsen J, Wallaschofski H, Friedrich N, Spielhagen C, Rettig R, Ittermann T, Nauck M, Hannemann A.
    Bone; 2013 Dec 23; 57(2):399-404. PubMed ID: 24076251
    [Abstract] [Full Text] [Related]

  • 10. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Michalska D, Luchavova M, Zikan V, Raska I, Kubena AA, Stepan JJ.
    Osteoporos Int; 2012 Dec 23; 23(12):2885-91. PubMed ID: 22426952
    [Abstract] [Full Text] [Related]

  • 11. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
    Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM.
    Osteoporos Int; 2019 Mar 23; 30(3):667-673. PubMed ID: 30635696
    [Abstract] [Full Text] [Related]

  • 12. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R, Seppänen J, Laitinen K, Katajamäki A, Risteli J, Välimäki MJ.
    Osteoporos Int; 2005 Sep 23; 16(9):1109-16. PubMed ID: 15605190
    [Abstract] [Full Text] [Related]

  • 13. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Adami S, Rossini M.
    J Bone Miner Res; 2012 Nov 23; 27(11):2259-63. PubMed ID: 22692843
    [Abstract] [Full Text] [Related]

  • 14. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
    McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD.
    Osteoporos Int; 2013 Jan 23; 24(1):227-35. PubMed ID: 22776860
    [Abstract] [Full Text] [Related]

  • 15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM, Iranikhah MM, Wilborn TW.
    Pharmacotherapy; 2011 May 23; 31(5):510-23. PubMed ID: 21923432
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul 23; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 19. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug 23; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

  • 20. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study.
    Brown JP, Dempster DW, Ding B, Dent-Acosta R, San Martin J, Grauer A, Wagman RB, Zanchetta J.
    J Bone Miner Res; 2011 Nov 23; 26(11):2737-44. PubMed ID: 21735475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.